Sana Biotechnology (NASDAQ:SANA) Announces Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Sana Biotechnology (NASDAQ:SANA) released its quarterly earnings data on Thursday. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01, FiscalAI reports.

Sana Biotechnology Price Performance

Sana Biotechnology stock traded up $0.03 during midday trading on Friday, hitting $2.37. 2,288,443 shares of the company were exchanged, compared to its average volume of 2,997,985. Sana Biotechnology has a fifty-two week low of $2.22 and a fifty-two week high of $5.49. The company has a market cap of $709.48 million, a PE ratio of -4.47 and a beta of 2.30. The company’s fifty day moving average price is $2.88 and its 200-day moving average price is $3.35.

Analyst Ratings Changes

A number of research firms have recently issued reports on SANA. Weiss Ratings restated a “sell (d-)” rating on shares of Sana Biotechnology in a research report on Wednesday, October 21st. Bank of America reduced their price target on Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. TD Cowen raised shares of Sana Biotechnology to a “strong-buy” rating in a research report on Monday, August 24th. Finally, Wall Street Zen raised Sana Biotechnology from a “sell” rating to a “hold” rating in a report on Saturday. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.60.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc is a clinical-stage biotechnology company focused on developing engineered cell and gene therapies for serious diseases. The company’s approach is designed to create durable treatments by modifying cells outside or inside the body and using them to replace, repair, or supplement damaged or missing biological functions.

Sana is developing proprietary technologies intended to support the delivery and persistence of therapeutic cells. These include platforms for engineering cells to evade immune-system detection, potentially allowing donor-derived cells to be used without extensive immune suppression, as well as methods for delivering genetic instructions directly to targeted tissues.